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SUMMARY
A 34-year-old 13-week pregnant woman presented with
hypertension refractory to medical therapy and on
workup was found to have a right adrenal mass. Due to
her persistent increased blood pressure she was advised
urinary vanillylmandelic acid (VMA) and its level was
raised. MRI of the abdomen showed a well-circumcised
lesion in the right adrenal of 3.0×2.5 cm suggestive of
pheochromocytoma. The patient was started on
antihypertensives including α-blockers and β-blockers
and planned for right open adrenalectomy.
Intraoperatively, blood pressure was raised up to
180/110 mm Hg on slight manipulation of adrenal gland
which was controlled with glyceryl-trinitrate and volatile
agents. Postoperatively urinary VMA decreased to normal
range and all antihypertensives were gradually stopped.
She had uneventful pregnancy and delivered vaginally.
This case report highlights the importance of surgical
management of pheochromocytoma in second trimester
of pregnancy to avoid catastrophic complications later in
pregnancy.
BACKGROUND
Pheochromocytoma (PCC) is a neuroendocrine
tumour of the adrenal medulla (originating in the
chromafﬁn cells). PCC is a very rare condition in
pregnancy and it carries signiﬁcant risks to the
mother as well as to the fetus. Therefore, PCC
should be considered as a possible cause of refrac-
tory hypertension in pregnancy and appropriate
investigations should be carried out. The diagnosis
can be established by measuring catecholamines
and metanephrines levels in the plasma (blood) or
through a 24-hour urine collection for VMA. The
tumour is generally localised by MRI during preg-
nancy. Deﬁnitive treatment of PCC is surgical but
initially it should be treated medically to control
blood pressure with α-adrenergic blockers, fol-
lowed by β-blockers. In this case report PCC was
detected in the second trimester, and managed
successfully.
CASE PRESENTATION
A 34-year pregnant woman was referred to our
clinic because of hypertension refractory to medical
therapy and right adrenal mass. She had two
normal deliveries before this pregnancy and had no
complications. She was diagnosed to have essential
hypertension when non-pregnant and was pre-
scribed ACE inhibitor (enalapril 10 mg twice daily).
Calcium channel blocker and β-blocker (amlodipine
10 mg four times a day and atenolol 50 mg twice
daily) were later added by the family physician due
to refractory hypertension. Meanwhile, the patient
became pregnant.
INVESTIGATIONS
Owing to persistent increased blood pressure (BP)
she was advised urinary vanillylmandelic acid
(VMA) which was raised 30 mg/24 h (normal level
2–7 mg/24 h). Later the family physician advised
ultrasound which revealed an adrenal mass. She
had an MRI subsequently which conﬁrmed a well-
circumscibed lesion in the right adrenal mass of
3.0×2.5 cm suggestive of PCC (ﬁgures 1 and 2).
DIFFERENTIAL DIAGNOSIS
Hypertension during pregnancy is usually attribut-
able to pre-eclampsia (pregnancy-induced hyper-
tension) or chronic hypertension but secondary
causes of hypertension should be considered in
patients refractory to medical therapy. These
include renal vascular hypertension, coarctation of
the aorta and adrenal causes of hypertension
(Cushing syndrome, Conn’s syndrome, PCC).
TREATMENT
Soon after these diagnostic tests, the patient devel-
oped symptoms including sweating, ﬂushing and
chest pain with BP 200/120 mm Hg. Cardiac evalu-
ation was performed including ECG and echocar-
diogram which revealed no abnormality. The
treatment was revised and phenoxybenzamine
10 mg thrice daily was initiated resulting in
adequate control of hypertension as well as symp-
toms. Obstetric examination and ultrasound of the
fetus showed a single alive fetus with normal fetal
growth parameters. Considering the risk of hyper-
tension during pregnancy and the possibility of
aggravation during later stages of pregnancy we
decided to excise the mass. Surgical risk and risk to
fetus was discussed with the patient. Obstetrician
also agreed with the plan and counselled the
patient about the possible chances of miscarriage.
The patient was planned for adrenalectomy during
13th week of pregnancy.
The patient was admitted for right open adrena-
lectomy and started on progesterone pessaries
400 mg twice daily. Intraoperatively, BP raised to
180/110 mm Hg on slight manipulation of adrenal
gland which was controlled by the anaesthetist with
glyceryl-trinitrate and volatile agents included iso-
ﬂurane and nitrous to control the BP during
surgery. Operative time was 160 min with a blood
loss of only 200 mL and without any need of trans-
fusion. Postoperatively in the recovery room the
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obstetrician performed ultrasound and the fetal heart was
checked, which was found normal.
For pain management the anaesthetist started pethidine via
patient-controlled intravenous analgesia (PCIA). She was pre-
scribed intravenous paracetamol and morphine after discontinu-
ation of PCIA. The patient was kept in the intensive care unit
for labile BP for 2 days which was managed by ﬂuid resuscita-
tion and adjustment of dosage of antihypertensives. The endo-
crinologist gradually tapered off the antihypertensive
medication over 3 days postoperatively. On second postoperative
day, slight per vaginal spotting was noticed which settled with
observation. The patient was discharged on seventh POD with
propranolol 10 mg twice daily and progesterone pessaries
400 mg twice daily.
OUTCOME AND FOLLOW-UP
The patient was followed up in the clinic after 2 weeks, she was
ﬁne with normal fetal growth parameters on ultrasound.
Urinary VMA decreased to normal range and all antihyperten-
sives were stopped. She was followed up in the obstetric clinic,
had safe pregnancy and delivered vaginally at term.
DISCUSSION
PCC accounts for 0.1–1% of all cases of hypertension. Precise
incidence in pregnancy is difﬁcult to determine but more than
200 cases have been reported in the published literature. PCC
is a very rare neuroendocrine tumour which originates from
the adrenal medulla (chromafﬁn cells). This tumour is notori-
ous for its devastating consequences.1 2 PCC is occasionally
referred to as ‘10% tumors’ because 10% are bilateral, 10%
are extra-adrenal and 10% are malignant.2 3 In pregnancy, the
presence of PCC may be difﬁcult to detect owing to the more
prevalent diagnosis of pregnancy-induced hypertension. It is
usually suspected when patient is not responding well to anti-
hypertensives. Untreated PCC carries a risk of mortality for
the mother and the fetus, as high as 58%.4 5 Early diagnosis is
vital and symptoms and signs vary which includes: hyperten-
sion (98% of cases), orthostatic hypotension, palpitations,
tachycardia, headache, sweating, seizure disorders and anxiety
attacks. Other symptoms are chest pain, nausea and vomiting,
pallor and ﬂushing.2 6 Pregnancy does not alter urinary cate-
cholamines hence diagnosis is conﬁrmed by 24 h urine VMA,
metanephrines or catecholamines. Metanephrines and cate-
cholamines can be measured in the blood as well.7 8 In adults,
approximately 80% of PCC are unilateral and solitary. For
localisation ultrasound of the abdomen should be performed
as it is easily accessible, cheap and a safe modality in preg-
nancy and has 89–97% sensitivity. MR has the advantages of
greater accuracy, high-quality images and lack of ionising radi-
ation.9–12 As the complication rate increases with progression
of pregnancy, late ﬁrst trimester and second trimester are the
ideal times for surgical treatment after organogenesis is com-
pleted. Surgery should be avoided in early ﬁrst trimester
because of high chances of miscarriage and in late second tri-
mester and third trimester because of abdominal exploration
and access is difﬁcult.12 13
PCC should always be treated ﬁrst medically to stabilise the
BP and symptoms. α-Adrenoceptor blockade that is either phe-
noxybenzamine or prazosin and β-blockade is used to control
tachycardia and dysrhythmia.8 11 12 14 The aim of this pre-
treatment is twofold: ﬁrst, before undergoing surgery, blood
Figure 1 Abdominal MRI (coronal
view) showing the right adrenal mass
(arrow).
Figure 2 Abdominal MRI (axial view) showing the right adrenal mass
(arrow).
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pressure, heart rate and volume depletion should be restored
as far as possible. Second, the patient should be protected
from the toxic cardiovascular effects of preoperative surges of
catecholamines.1 15 The deﬁnitive treatment of PCC is surgical
excision either open, laparoscopic or robotic.4 13 A brief litera-
ture review showed that patients with PCC during pregnancy
were managed with one of the two approaches. First, medically
up to the end of pregnancy and then tumour excision along
with C section.2 16 17 This approach appears to be more suit-
able for patients who present late in pregnancy and/or
adequately manageable with antihypertensives. The second
approach is resection of PCC preferably during the second tri-
mester. Robotic adrenalectomy during pregnancy has been
reported and the patient had no perioperative complication.13
Individualised management is appropriate as no single protocol
is suitable for all patients given the rarity and the complexity
of the problem.
Learning points
▸ Although pheochromocytoma (PCC) has been treated by
controlling blood pressure in the pregnancy, surgical
treatment in the second trimester is preferable.
▸ Patients presenting early in the second trimester are best
candidates owing to low risk for maternal–fetal death
during this period compared with the ﬁrst or third trimester.
▸ Management of PCC should be multidisciplinary in which
the endocrinologist, obstetrician, urologist and the
anaesthesiologist should be included to minimise the
probabilities of complications.
▸ Strict blood pressure control perioperatively is the key to
avoid complications.
▸ PCC must be suspected as a cause of refractory hypertension
in pregnancy.
Acknowledgements The authors thank Ms Munira Amin for her help with
literature search.
Contributors MAM and WA drafted the manuscript and performed literature
search. FA is the consultant surgeon responsible for patient management.
Competing interests None.
Patient consent Obtained.
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1 Lenders JW. Endocrine disorders in pregnancy: pheochromocytoma and pregnancy:
a deceptive connection. Eur J Endocrinol 2012;166:143–50.
2 Almog B, Kupferminc MJ, Many A, et al. Pheochromocytoma in pregnancy—a case
report and review of the literature. Acta Obstet Gynecol Scand 2000;79:709–11.
3 Greene J, Guay A. New perspectives in pheochromocytoma. Urol Clin North Am
1989;16:487.
4 Von Moll L, McEwan AJ, Shapiro B, et al. Iodine-131 MIBG scintigraphy of
neuroendocrine tumors other than pheochromocytoma and neuroblastoma. J Nucl
Med 1987;28:979.
5 Oliva R, Angelos P, Kaplan E, et al. Pheochromocytoma in pregnancy a case series
and review. Hypertension 2010;55:600–6.
6 Smith CM, Wigent PJ. Pheochromocytoma in pregnancy: considerations for the
advanced practice nurse. J Perinat Neonatal Nurs 1998;12:11–25.
7 Kaplan NM, Victor RG. Kaplan’s clinical hypertension. Lippincott Williams & Wilkins,
2010.
8 Song Y, Liu J, Li H, et al. Outcomes of concurrent Caesarean delivery and
pheochromocytoma resection in late pregnancy. Intern Med J 2013;43:588–91.
9 Botchan A, Hauser R, Kupferminc M, et al. Pheochromocytoma in pregnancy: case
report and review of the literature. Obstet Gynecol Survey 1995;50:321–7.
10 Kennelly M, Ball S, Robson V, et al. Difﬁcult alpha-adrenergic blockade of a
phaeochromocytoma in a twin pregnancy. J Obstet Gynecol 2007;27:729–30.
11 Takongmo S, Wawo YE, Gonsu KH, et al. Diagnosis of pheochromocytoma in
Yaoundé (Cameroon): a study of nine cases. Med Trop 2010;70:274.
12 Harper M, Murnaghan G, Kennedy L, et al. Phaeochromocytoma in pregnancy. Five
cases and a review of the literature. BJOG 1989;96:594–606.
13 Kalra JK, Jain V, Bagga R, et al. Pheochromocytoma associated with pregnancy.
J Obstet Gynaecol Res 2003;29:305–8.
14 Podolsky ER, Feo L, Brooks AD, et al. Robotic resection of pheochromocytoma in
the second trimester of pregnancy. JSLS 2010;14:303.
15 Kinney M, Narr BJ, Warner MA. Perioperative management of pheochromocytoma.
J Cardiothorac Vasc Anesth 2002;16:359.
16 Lowy C. Endocrine emergencies in pregnancy. Clin Endocrinol Metab 1980;9:569.
17 Leak D, Carroll J, Robinson D, et al. Management of pheochromocytoma during
pregnancy. Can Med Assoc J 1977;116:371.
Copyright 2014 BMJ Publishing Group. All rights reserved. For permission to reuse any of this content visit
http://group.bmj.com/group/rights-licensing/permissions.
BMJ Case Report Fellows may re-use this article for personal use and teaching without any further permission.
Become a Fellow of BMJ Case Reports today and you can:
▸ Submit as many cases as you like
▸ Enjoy fast sympathetic peer review and rapid publication of accepted articles
▸ Access all the published articles
▸ Re-use any of the published material for personal use and teaching without further permission
For information on Institutional Fellowships contact consortiasales@bmjgroup.com
Visit casereports.bmj.com for more articles like this and to become a Fellow
Memon MA, et al. BMJ Case Rep 2014. doi:10.1136/bcr-2013-202838 3
Unusual association of diseases/symptoms
